With Bardet-Biedl Syndrome (BBS) increasingly impacting populations worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the need for safer and more effective therapies is growing. DelveInsight reports that the BBS pipeline includes 8+ pharmaceutical and biotech companies developing 1+ therapeutic candidates for Bardet-Biedl Syndrome. These treatments are progressing through various stages of clinical and preclinical development, highlighting significant innovation and dedication to addressing this critical health challenge.
DelveInsight’s “Bardet-Biedl Syndrome Pipeline Insight 2025” delivers a comprehensive analysis of the current R&D landscape, covering clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is an essential resource for researchers, investors, and decision-makers seeking insights into the evolving Bardet-Biedl Syndrome therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Bardet-Biedl Syndrome Drug Development @ https://www.delveinsight.com/report-store/bardet-biedl-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
-
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
-
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
-
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
-
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
-
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
-
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
-
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
-
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Key Takeaways from the Bardet-Biedl Syndrome Pipeline Report
-
DelveInsight’s Bardet-Biedl Syndrome pipeline report highlights a dynamic landscape with 8+ active companies developing 1+ therapeutic candidates for the treatment of Bardet-Biedl Syndrome.
-
In December 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Imcivree (setmelanotide), permitting its use for chronic weight management in adults and children aged 2 years and older with obesity caused by Bardet-Biedl Syndrome. This approval was supported by clinical trial results showing meaningful reductions in both weight and hunger among BBS patients.
-
Key companies, including Rhythm Pharmaceuticals and others, are actively exploring new therapies to enhance the Bardet-Biedl Syndrome treatment landscape. Promising pipeline candidates include Setmelanotide and additional therapies in various stages of development.
Bardet-Biedl Syndrome Overview:
Bardet–Biedl syndrome (BBS) is a rare, autosomal recessive genetic disorder classified as a ciliopathy. It is associated with mutations in at least 20 genes (BBS1–BBS20) and exhibits an oligogenic inheritance pattern. BBS proteins, located in the centrosome, are essential for the formation and function of cilia. Dysfunction of these proteins impacts multiple organ systems that depend on ciliated cells, resulting in a broad spectrum of symptoms. Clinical signs of BBS usually develop gradually during the first decade of life, with most cases diagnosed in late childhood or early adulthood.
Download the Bardet-Biedl Syndrome sample report to know in detail about the Bardet-Biedl Syndrome treatment market @ https://www.delveinsight.com/sample-request/bardet-biedl-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Bardet-Biedl Syndrome Pipeline Analysis
The Bardet-Biedl Syndrome pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Bardet-Biedl Syndrome Market.
-
Categorizes Bardet-Biedl Syndrome therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Bardet-Biedl Syndrome drugs under development based on:
-
Stage of development
-
Bardet-Biedl Syndrome Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Bardet-Biedl Syndrome Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Bardet-Biedl Syndrome Licensing agreements
-
Funding and investment activities supporting future Bardet-Biedl Syndrome market advancement.
-
Unlock key insights into emerging Bardet-Biedl Syndrome therapies and market strategies here: https://www.delveinsight.com/report-store/bardet-biedl-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Bardet-Biedl Syndrome Emerging Drugs
Setmelanotide: Rhythm Pharmaceuticals
Setmelanotide is an advanced investigational therapy that functions as a melanocortin-4 receptor (MC4R) agonist. It aims to restore the activity of the MC4R pathway, which can be disrupted by genetic mutations upstream of the receptor, thereby helping to curb excessive appetite and support weight loss. The U.S. FDA has granted Setmelanotide Breakthrough Therapy Designation for the treatment of Bardet-Biedl syndrome (BBS), and it has also received Orphan Drug Designation from both the FDA and the European Commission for this condition.
Bardet-Biedl Syndrome Pipeline Therapeutic Assessment
Bardet-Biedl Syndrome Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Bardet-Biedl Syndrome By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Bardet-Biedl Syndrome Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Bardet-Biedl Syndrome Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Bardet-Biedl Syndrome therapies and key Bardet-Biedl Syndrome companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Bardet-Biedl Syndrome Current Treatment Patterns
8. Bardet-Biedl Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
1. Bardet-Biedl Syndrome Late-Stage Products (Phase-III)
7. Bardet-Biedl Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
1. Inactive Products
11. Dormant Products
12. Bardet-Biedl Syndrome Discontinued Products
13. Bardet-Biedl Syndrome Product Profiles
18. Bardet-Biedl Syndrome Key Companies
15. Bardet-Biedl Syndrome Key Products
11. Dormant and Discontinued Products
17. Bardet-Biedl Syndrome Unmet Needs
18. Bardet-Biedl Syndrome Future Perspectives
19. Bardet-Biedl Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Bardet-Biedl Syndrome pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/